16.62
+0.97%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Aurinia Pharmaceuticals
From its filings with the US Securities and Exchange Commission
Aurinia Pharmaceuticals is based in Edmonton, Alberta, Canada. Its shares trade on Nasdaq under the ticker AUPH. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $283.1m and net income of $287.2m. At that date it held total assets of $751.6m and shareholders' equity of $581.3m.
Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (“LN”). Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (“BAFF”) and a proliferation-inducing ligand (“APRIL”) for the potential treatment of autoimmune diseases.
Aurinia sells LUPKYNIS to two specialty pharmacies and a specialty distributor in the United States (“U.S.”), and Aurinia sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (“Otsuka”), for the European and Japanese market.
For the year ended December 31, 2025, net product sales were $271.3 million, up 25% compared to $216.2 million in 2024.
For the year ended December 31, 2025, cash flows from operating activities were $135.7 million, up 206% compared to $44.4 million in 2024.
As of December 31, 2025, Aurinia had cash, cash equivalents, restricted cash and investments of $398.0 million, compared to $358.5 million at December 31, 2024. For the year ended December 31, 2025, the Company repurchased 12.2 million of its common shares for $98.2 million.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 19 Sept 2000
- Employees
- 128
- Website
- auriniapharma.com ↗
- Head office
- #140, 14315 - 118 AVENUE, EDMONTON, A0, T5L 4S6
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Kevin TangIndependent Chairman of the Board
- Mr. Peter GreenleafPresident, Chief Executive Officer, Director, since 2019$6.4m
- Mr. Joseph MillerChief Financial Officer$2.3m
- Mr. Matthew DonleyChief Operating Officer$2.5m
- Mr. Stephen RobertsonExecutive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary$2.2m
- Dr. Greg KeenanChief Medical Officer$1.3m
- Mr. Jeffrey BaileyIndependent Director$264,494
- Dr. David JayneIndependent Director$251,329
- Mr. Craig JohnsonIndependent Director$346,724
- Ms. Jill LeversageIndependent Director$269,997
- Dr. Karen SmithIndependent Director$256,994
- Ms. Andrea ChristopherExecutive Director, Corporate Communications and Investor Relations, since 2025
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 40
- Environment
- 30
- Social
- 39
- Governance
- 51
- Direct emissions (scope 1)
- 0 t
- Energy emissions (scope 2)
- 218.43 t
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Aurinia Pharmaceuticals Inc has a strong scientific and research team dedicated to developing innovative pharmaceutical products.
- The company has a robust pipeline of drug candidates targeting multiple therapeutic areas.
- Aurinia Pharmaceuticals has secured various partnerships and collaborations to support its drug development and commercialization efforts.
Weaknesses
- Aurinia Pharmaceuticals heavily relies on the success of its drug candidates, which makes the company vulnerable to failures in clinical trials or regulatory challenges.
- The company might face difficulties in obtaining necessary financing for research, development, and marketing activities.
- Aurinia Pharmaceuticals is currently dependent on a limited number of key markets, which could pose risks in terms of market diversification.
Opportunities
- The increasing prevalence of various diseases, coupled with growing awareness for effective treatments, presents Aurinia Pharmaceuticals with significant market opportunities.
- Expanding into emerging markets could provide the company with additional revenue streams and access to a larger patient population.
- Advancements in technology and scientific research offer Aurinia Pharmaceuticals the chance to develop breakthrough therapies and gain a competitive advantage.
Threats
- Intense competition within the pharmaceutical industry may impede Aurinia Pharmaceuticals' market share and pricing power.
- Changes in healthcare regulations and policies could impact the company's ability to obtain regulatory approvals and reimbursement for its products.
- Potential intellectual property disputes and patent expirations pose a threat to Aurinia Pharmaceuticals' ability to protect its innovations and maintain a competitive edge.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.